MLN4924 is a potent and selective small-molecule inhibitor of NEDD8-activating enzyme (NAE) (IC50 = 4 nM) [1,2], and is selective relative to the closely related enzymes UAE, SAE, UBA6 and ATG7 (IC50 = 1.5, 8.2, 1.8 and >10 μM, respectively) [2]. MLN4924 has a multifaceted mechanism of action that is characterized by the induction of DNA re-replication and DNA damage, increased oxidative stress, inhibition of NF-B activity, apoptotic cell death, and cellular senescence [3].
MLN4924 Treatment of HCT-116 cells for 24 h resulted in a dose-dependent decrease of Ubc12-NEDD8 thioester and NEDD8-cullin conjugates, with an IC50 < 0.1 μM [2], resulting in a reciprocal increase in the abundance of the known CRL substrates CDT1, p27 and NRF2 (also known as NFE2L2), c-Jun27, HIF1α, cyclin E29, CDC25A, EMI1 (also known as FBXO5) and phosphorylated IκBα, but not non-CRL substrates [2]. MLN4924 treatment of human-tumour-derived cell lines, including HCT-116(colon), Calu-6 (lung), SKOV-3 (ovarian), H460 (lung), DLD-1 (colon), CWR22 (prostate) and OCI-LY19 (lymphoma), resulted in S-phase-defective phenotypes [2]. Potent inhibition of MLN4924 of cell viability was observed across 17 lymphoma cell lines tested in an ATPlite viability assay, with EC50 values of 10 to 244nM [1].
In OCI-Ly10 xenografts, a dose- and time-dependent increase in pIκBα levels was observed after MLN4924 treatment (10, 30, or 60 mg/kg, subcutaneous), with peak elevation occurring 2 hours after dose and levels returning to baseline at 8 hours after dose. A consequence of inhibiting NAE and NF-κB signaling in OCI-Ly10 xenografts was the induction of apoptosis 8 to 12 hours after a single dose of 60 mg/kg MLN4924, as evidenced by detection of cleaved caspase-3 [1]. A single dose of MLN4924 resulted in a dose- and time-dependent decrease of NEDD8-cullin levels as early as 30 min after administration of MLN4924 (10, 30 or 60 mg/kg, subcutaneous), with maximal effect 1-2 h post-dose on HCT-116 tumour-bearing mice [2].
References:
[1]. Milhollen M A, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma[J]. Blood, The Journal of the American Society of Hematology, 2010, 116(9): 1515-1523.
[2]. Soucy T A, Smith P G, Milhollen M A, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer[J]. Nature, 2009, 458(7239): 732-736.
[3]. Nawrocki S T, Griffin P, Kelly K R, et al. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy[J]. Expert opinion on investigational drugs, 2012, 21(10): 1563-1573.
MLN4924 是一种有效的选择性 NEDD8 激活酶 (NAE) 小分子抑制剂 (IC50 = 4 nM) [1,2]，并且相对于密切相关的酶 UAE、SAE、UBA6 和 ATG7 具有选择性（ IC50 = 1.5、8.2、1.8 和 >；分别为 10 μM）[2]。 MLN4924 具有多方面的作用机制，其特征在于诱导 DNA 再复制和 DNA 损伤、增加氧化应激、抑制 NF-B 活性、凋亡细胞死亡和细胞衰老[3] .
MLN4924 处理 HCT-116 细胞 24 小时导致 Ubc12-NEDD8 硫酯和 NEDD8-cullin 结合物呈剂量依赖性降低，IC50 为 <； 0.1 μM [2]，导致已知 CRL 底物 CDT1、p27 和 NRF2（也称为 NFE2L2）、c-Jun27、HIF1α、细胞周期蛋白 E29、CDC25A、EMI1 的丰度相互增加（也称为 FBXO5）和磷酸化 IκBα，但不是非 CRL 底物[2]。 MLN4924 治疗人肿瘤来源的细胞系，包括 HCT-116（结肠）、Calu-6（肺）、SKOV-3（卵巢）、H460（肺）、DLD-1（结肠）、CWR22（前列腺）和OCI-LY19（淋巴瘤）导致 S 期缺陷表型 [2]。在 ATPlite 活力测定中测试的 17 种淋巴瘤细胞系中观察到 MLN4924 对细胞活力的有效抑制，EC50 值为 10 至 244nM [1]。
在 OCI-Ly10 异种移植物中，在 MLN4924 治疗（10、30 或 60 毫克/千克，皮下注射）后观察到 pIκBα 水平呈剂量和时间依赖性升高，给药后 2 小时出现峰值升高，水平恢复给药后 8 小时达到基线。在 OCI-Ly10 异种移植物中抑制 NAE 和 NF-κB 信号传导的结果是在单剂量 60 mg/kg MLN4924 后 8 至 12 小时诱导细胞凋亡，检测到裂解的 caspase-3 [1] 。早在施用 MLN4924（10、30 或 60 mg/kg，皮下）后 30 分钟，单剂量 MLN4924 就会导致 NEDD8-cullin 水平的剂量和时间依赖性降低，在 1-2 小时后产生最大效果-对携带 HCT-116 肿瘤的小鼠的剂量[2]。